Castle Biosciences (CSTL) Cash from Financing Activities (2018 - 2026)

Castle Biosciences has disclosed Cash from Financing Activities across 9 years of filings, most recently posting -$5.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$5.0 million, down 224.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.4 million (down 72.33% YoY), and the FY2025 annual result was -$7.0 million, down 213.37% from the prior year.
• Cash from Financing Activities came in at -$5.0 million for Q1 2026 at Castle Biosciences, down from -$4.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $10.6 million in Q1 2024 to a low of -$5.4 million in Q4 2024.
• The 5-year median for Cash from Financing Activities is $45000.0 (2023), against an average of -$390411.8.
• Across the five-year window, Cash from Financing Activities tumbled 695.24% in 2022 and soared 1762.22% in 2024, its largest moves.
• Castle Biosciences' Cash from Financing Activities stood at -$750000.0 in 2022, then sank by 339.6% to -$3.3 million in 2023, then slumped by 63.33% to -$5.4 million in 2024, then rose by 14.78% to -$4.6 million in 2025, then declined by 9.68% to -$5.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$5.0 million (Q1 2026), -$4.6 million (Q4 2025), and -$919000.0 (Q3 2025), per Business Quant data.